A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Pemetrexed (Primary) ; Cisplatin
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Oct 2016 Results of pooled analysis of three phase III trials (JMDB, PARAMOUNT and JMII; n=1064) were presented at the 41st European Society for Medical Oncology Congress
    • 11 Jun 2008 The expected completion date for this trial was 1 Mar 2008 instead of 1 Jun 2008 according to clinicaltrials.gov.
    • 28 May 2008 Primary endpoint met; results to be reported in the Journal of Clinical Oncology, according to an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top